Prevenar 7 + Prevenar 13

Prevenar 7 (PCV7) and Prevenar 13 (PCV13) are pneumococcal conjugate vaccines (PCVs) developed by Pfizer to prevent invasive diseases caused by Streptococcus pneumoniae, such as pneumonia, meningitis, and sepsis. PCV7, the first conjugate vaccine, targets seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F), while PCV13 expanded coverage to thirteen serotypes by adding 1, 3, 5, 6A, 7F, and 19A. Both vaccines utilize the CRM197 carrier protein to enhance immunogenicity, particularly in infants and young children. The specific context provided relates to a long-term observational study led by University Hospital Southampton NHS Foundation Trust, which monitors nasopharyngeal carriage and serotype replacement in the pediatric population following the introduction of these vaccines into the UK's national immunization schedule.

Brand names

Prevenar 13Prevenar13Prevenar-13PrevenarPrevnar 13Prevnar13Prevnar-13Prevnar

Other names

7-valent pneumococcal conjugate vaccine13-valent pneumococcal conjugate vaccineheptavalent pneumococcal conjugate vaccine13-valent pneumococcal polysaccharide conjugate vaccine